Comments
Pharmaceuticals firm Divi’s Laboratories today reported 63.15 per cent increase in standalone net profit for the quarter ended June 30, 2012, at Rs 167.38 crore, driven by higher sales realisation.
The company had posted a net profit of Rs 102.59 crore in the same period last fiscal.
During the first quarter this fiscal, net sales were at Rs 468.41 crore as against Rs 361.28 crore in the year-ago period, up 29.65 per cent, Divi’s Laboratories said in a filing to BSE.
Total expense during the period under review stood at Rs 295.45 crore as against Rs 244.4 crore in the corresponding period last fiscal, it said.
The company’s Unit 2 near Visakhapatnam has undergone three cGMP inspections during June-July this year. One of the inspections was by TGA of Australia for active pharma ingredients (APIs), it said.
“The other two inspections were by the USFDA, one for nutraceuticals and the other for APIs. All the three inspections had no major observations,” the company said.
Shares of Divi’s Laboratories were trading at a new high of Rs 1,128.50 per share in afternoon trade on the BSE, up 1.02 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.